South Africa’s third largest pharmaceutical company is to
acquire a 30% stake in the connected healthcare company, Brandmed for an
upfront cash consideration of R65 million. Cipla says in a statement that the
acquisition is in recognition of the importance of the critical shift to a more
patient-centric, integrated and predictive healthcare environment. The move
comes only two months after Cipla announced a similar partnership in India with
Wellthy Therapeutics to offer a clinically-validated digital disease management
platform to patients in cardio-metabolic health.
Cipla Medpro CEO, Paul Miller says the stake in Brandmed
will help the company to transition healthcare from being reactive to a “proactive
and real-time monitoring model” that focuses on promoting wellness instead of
“This aligns with Cipla’s vision and focus on ‘human care’
and a future where good health is expected, not for the few, but for the many,”
Founded in 2014, Brandmed has developed a unique fully
integrated end-to-end solution to address outcomes and value-based care for
patients with chronic lifestyle and non-communicable diseases (NCDs) such as
hypertension, diabetes, high cholesterol, asthma and chronic obstructive
pulmonary disease. A subsidiary of Brandmed, KardioGroup, was recently awarded
the prestigious Frost & Sullivan South African Product Line Strategy
Leadership, Internet of Medical Things South Africa.
The Brandmed ecosystem was developed in South Africa to seamlessly
integrate a combination of connected solutions across the health continuum for
patients, healthcare professionals, practices and institutions, and aims to
deliver personalised patient care.
Paul Miller, CEO of Cipla Medpro, said: “This transaction
will help to transition healthcare from being reactive to a proactive and
real-time monitoring model that focuses on promoting wellness instead of
managing illness. This aligns with Cipla’s vision and focus on ‘human care’ and
a future where good health is expected, not for the few, but for the many.”
“By pairing our strengths with Brandmed’ s innovative,
patient-centric approach to healthcare, Cipla Medpro will enhance its diverse
portfolio in the NCD area to provide holistic care to patients from awareness
through to disease management, thereby enabling patient adherence and
compliance,” Millerr said.
Brandmed founder is South African cardiologist, Dr Riaz
Motara emphasised the importance of innovative solutions to manage the disease
burden, saying that it can’t be done with drugs alone.
medical expertise with ground-breaking technology to deliver better patient
care and offer an integrated disease management solution. We’re also shifting
the focus from managing diseases in separate silos to a comprehensive risk
reduction and treatment approach. Greater success in patient health outcomes,
value-based care and efficiencies could be achieved in South Africa if more
healthcare stakeholders are willing to work together,” said Motara.